Alicia Gonzalez-Martinez1, Víctor Fanjul2, Carmen Ramos1,3, Jorge Serrano Ballesteros4, Marta Bustamante4, Almudena Villa Martí4, Claudia Álvarez4, Yaiza García Del Álamo4, José Vivancos1, Ana Beatriz Gago-Veiga1,3. 1. Neurology Department, Hospital Universitario de La Princesa and Instituto de Investigación Sanitaria de La Princesa, Madrid, Spain. 2. Biostatistician at Savana and Headache Unit Collaborator at Department of Neurology, Hospital Universitario de La Princesa, Madrid, Spain. 3. Headache Unit, Neurology Department, Hospital Universitario de La Princesa and Instituto de Investigación Sanitaria de La Princesa, Madrid, Spain. 4. Internal Medicine Department, Hospital Universitario de La Princesa and Instituto de Investigación Sanitaria de La Princesa, Madrid, Spain.
Abstract
BACKGROUND AND PURPOSE: Headache is an important manifestation during SARS-CoV-2 infection. In this study, the aim was to identify factors associated with headache in COVID-19 and headache characteristics. METHODS: This case-control study includes COVID-19 hospitalized patients with pneumonia during March 2020. Controls comprise COVID-19 patients without headache and the cases are COVID-19 patients with headache. Demographic, clinical and laboratory data were obtained from the medical records. Headache characteristics were evaluated by semi-structured telephonic interview after discharge. RESULTS: Of a total of 379 COVID-19 patients, 48 (13%) developed headache. Amongst these, 30 (62%) were men and the median age was 57.9 (47-73) years. Headache was associated with younger age, fewer comorbidities and reduced mortality, as well as with low levels of C-reactive protein, mild acute respiratory distress syndrome and oropharyngeal symptoms. A logistic multiple regression model revealed that headache was directly associated with D-dimer and creatinine levels, the use of high flow nasal cannula and arthromyalgia, whilst urea levels, beta-lactamic treatment and hypertension were negatively associated with headache. COVID-19-associated headache characteristics were available for 23/48 (48%) patients. Headache was the onset symptom in 8/20 (40%) patients, of mild or moderate intensity in 17/20 (85%) patients, with oppressive characteristics in 17/18 (94%) and of holocranial 8/19 (42%) or temporal 7/19 (37%) localization. CONCLUSIONS: Our results show that headache is associated with a more benign SARS-CoV-2 infection. COVID-19-associated headache appears as an early symptom and as a novel headache with characteristics of headache attributed to systemic viral infection. Further research addressing the underlying mechanisms to confirm these findings is warranted.
BACKGROUND AND PURPOSE:Headache is an important manifestation during SARS-CoV-2 infection. In this study, the aim was to identify factors associated with headache in COVID-19 and headache characteristics. METHODS: This case-control study includes COVID-19 hospitalized patients with pneumonia during March 2020. Controls comprise COVID-19patients without headache and the cases are COVID-19patients with headache. Demographic, clinical and laboratory data were obtained from the medical records. Headache characteristics were evaluated by semi-structured telephonic interview after discharge. RESULTS: Of a total of 379 COVID-19patients, 48 (13%) developed headache. Amongst these, 30 (62%) were men and the median age was 57.9 (47-73) years. Headache was associated with younger age, fewer comorbidities and reduced mortality, as well as with low levels of C-reactive protein, mild acute respiratory distress syndrome and oropharyngeal symptoms. A logistic multiple regression model revealed that headache was directly associated with D-dimer and creatinine levels, the use of high flow nasal cannula and arthromyalgia, whilst urea levels, beta-lactamic treatment and hypertension were negatively associated with headache. COVID-19-associated headache characteristics were available for 23/48 (48%) patients. Headache was the onset symptom in 8/20 (40%) patients, of mild or moderate intensity in 17/20 (85%) patients, with oppressive characteristics in 17/18 (94%) and of holocranial 8/19 (42%) or temporal 7/19 (37%) localization. CONCLUSIONS: Our results show that headache is associated with a more benign SARS-CoV-2 infection. COVID-19-associated headache appears as an early symptom and as a novel headache with characteristics of headache attributed to systemic viral infection. Further research addressing the underlying mechanisms to confirm these findings is warranted.
Authors: Pedro Augusto Sampaio Rocha-Filho; Pedro Mota Albuquerque; Larissa Clementino Leite Sá Carvalho; Mylana Dandara Pereira Gama; João Eudes Magalhães Journal: J Headache Pain Date: 2022-01-03 Impact factor: 7.277
Authors: Bastien Paré; Marieke Rozendaal; Sacha Morin; Léa Kaufmann; Shawn M Simpson; Raphaël Poujol; Fatima Mostefai; Jean-Christophe Grenier; Henry Xing; Miguelle Sanchez; Ariane Yechouron; Ronald Racette; Julie G Hussin; Guy Wolf; Ivan Pavlov; Martin A Smith Journal: PLoS One Date: 2021-12-02 Impact factor: 3.240
Authors: David García-Azorín; Álvaro Sierra; Javier Trigo; Ana Alberdi; María Blanco; Ismael Calcerrada; Ana Cornejo; Miguel Cubero; Ana Gil; Cristina García-Iglesias; Ana Guiomar Lozano; Cristina Martínez Badillo; Carol Montilla; Marta Mora; Gabriela Núñez; Marina Paniagua; Carolina Pérez; María Rojas; Marta Ruiz; Leticia Sierra; María Luisa Hurtado; Ángel Luis Guerrero Peral Journal: Sci Rep Date: 2021-07-19 Impact factor: 4.379
Authors: César Fernández-de-Las-Peñas; Víctor Gómez-Mayordomo; David García-Azorín; Domingo Palacios-Ceña; Lidiane L Florencio; Angel L Guerrero; Valentín Hernández-Barrera; María L Cuadrado Journal: Front Hum Neurosci Date: 2021-06-28 Impact factor: 3.169